Format

Send to

Choose Destination
Neurology. 2016 Dec 6;87(23):2451-2456. Epub 2016 Nov 2.

Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.

Author information

1
From the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark.
2
From the Division of Brain Sciences (G.P., P.G.B., D.J.B., N.P.), Imperial College London; Imperial College NHS Trust (S.M.); Imanova Ltd (E.A.R.); National Parkinson Foundation International Centre of Excellence (E.A.R.), King's College London and National Institute for Health Research Biomedical Research Centre and King's College London; Institute of Neuroscience (D.J.B., N.P.), Newcastle University, UK; and Institute of Clinical Medicine (D.J.B., N.P.), University of Aarhus, Denmark. nicola.pavese@imperial.ac.uk.

Abstract

OBJECTIVE:

To investigate the relationship between hypothalamic D3 dopamine receptor availability and severity of sleep problems in Parkinson disease (PD).

METHODS:

Twelve patients were assessed with PET and the high-affinity dopamine D3 receptor radioligand [11C]-propyl-hexahydro-naphtho-oxazin ([11C]-PHNO). Severity of sleep problems was rated with appropriate subitems of the Unified Parkinson's Disease Rating Scale part I (patient questionnaire) and the Epworth Sleepiness Scale.

RESULTS:

We found that lower dopamine D3 receptor availability measured with [11C]-PHNO PET was associated with greater severity of excessive daytime sleepiness but not with problems of falling asleep or insomnia.

CONCLUSION:

In our cohort of patients with PD, the occurrence of excessive daytime sleepiness was linked to reductions in hypothalamic dopamine D3 receptor availability. If these preliminary findings are confirmed in larger cohorts of patients with polysomnographic characterization, selective pharmacologic modulation of the dopaminergic D3 system could be used to increase daytime alertness in patients with PD.

PMID:
27807182
PMCID:
PMC5177673
DOI:
10.1212/WNL.0000000000003396
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center